Destiny Pharma PLC

DEST.UK

$0.05

Closing

▼-25.53%

1D

▼-95.00%

YTD

DEST

BBG001STY997

Market cap

$4.33M

52 week high

$1.09

52 week low

$0.03

Volume

1,010,839

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $6.99/month

Market cap

$4.33M

Analysts' Rating

BUY

Price Target (Mean)

Unable to collect data for some field(s).

Total Analysts

0

P/E

Operating Margin

0.00%

Beta

0.09

Revenue Growth (Annual)

-

52 week high

$1.09

52 week low

$0.03

Div. Yield

%

EPS Annual Growth

0.00

Company Profile

Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company’s drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA). The Company’s earlier stage pipeline is focused on other indications including two, separate dermal programmes incorporating its XF platform. It is also collaborating with SporeGen on a novel SPOR-COV innate immune system boosting nasal spray for the prevention of COVID-19 and influenza.